3 FTSE 100 ‘coronavirus stocks’ I’d buy right now
The Motley Fool
Published Jul 24, 2020 11:11
Updated Jul 24, 2020 11:40
3 FTSE 100 ‘coronavirus stocks’ I’d buy right now
Many FTSE 100 stocks have suffered significantly in the coronavirus pandemic. However, some companies have seen an increase in the demand for their products over the past six months.
As such, now may be the time to buy a basket of these companies, ahead of a possible second wave later this year. Here are three FTSE 100 coronavirus stocks that might be worth considering today.
FTSE 100 coronavirus stocks AstraZeneca (LSE: AZN) is working flat out to produce a vaccine to help control the pandemic. It has already started production on Oxford University‘s leading candidate, which is still in its early phases of testing.
If the treatment is given the green light, AstraZeneca could benefit significantly. The FTSE 100 pharmaceutical group could see its sales and profits jump as virtually every country in the world is currently clamouring for a treatment.
This wouldn’t be a one-off for the group. Increased profits would allow Astra to reinvest more cashback into research and development. That could help improve the company’s growth for many years to come.
Therefore, there’s a strong chance investors buying this FTSE 100 coronavirus stock today could see high total returns in the years ahead.
Halma Halma (LSE: LON:HLMA) has reported a surge in demand for its health and safety kit over the past six months. This has helped the company outperform many of its FTSE 100 peers, which have seen sales fall.
Once again, this could help the company’s growth going forward. Halma has an excellent track record of buying up smaller businesses. It then integrates them into the wider group where they can benefit from its overall size and scale.
This approach has helped the company generate some of the best total returns for shareholders in the FTSE 100 over the past decade. Over the next few years, it may even accelerate its acquisition programme. Smaller peers may struggle in the current economic environment. This may mean they’re more susceptible to a takeover from Halma. It could use its excess profits generated over the past six months to fund an acquisition spree.
What’s more, considering the FTSE 100’s company’s performance in the first half of this year, a second wave of coronavirus may help support the group’s strategy. Long-term investors could be well rewarded here.
Reckitt Benckiser Reckitt Benckiser (LSE: RB) has also seen the demand for its products rise over the past six months. As one of the world’s leading producers of disinfectant products, the FTSE 100 company struggled to keep up with demand at the beginning of the crisis. However, over the past few months, management has got to grips with the situation.
Get The App
As a result, the company is well-placed to meet the world’s higher demand for cleaning and disinfectant products. Like the two companies listed above, the group may also be able to use profits produced over the past six months to help support growth in the years ahead.
Following a series of strategic missteps, Reckitt’s growth was floundering at the beginning of the year. But it now looks as if the company is back on track thanks, in part, to the pandemic. Only time will tell if the business has really put its problems behind it, but with its top-line set to grow significantly this year, it seems likely.
The post 3 FTSE 100 ‘coronavirus stocks’ I’d buy right now appeared first on The Motley Fool UK.
Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Halma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2020
First published on The Motley Fool
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.